Testovis (Testosterone)

Quick links to important sections

Testovis (Testosterone)

Treatment option: Hypogonadism

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Testovis (Testosterone)

Property Description
Active ingredient Testosterone propionate
Form Oil-based injectable solution
Pharmacological class Androgen, Steroid hormone
Common use Hormone replacement therapy (HRT)
Origin Synthetic derivative

Defining Testovis as an Androgen Hormone Replacement

Testovis is a pharmaceutical preparation containing the active ingredient Testosterone propionate, which functions as a replacement for the body's primary androgen hormone. This medication is classified as a prescription-only medicine (POM) and belongs to the pharmacological class of androgenic and anabolic steroids. The general purpose of Testovis is supporting hormone replacement therapy (HRT), which is clinically recognized for addressing physiological deficits linked to androgen deficiency in males.

Composition, Origin, and Pharmaceutical Form

Testovis is a single-ingredient product whose core is the synthetic derivative Testosterone propionate, chemically modified with a short-chain ester. This structure dictates that the dosage form is an oil-based injectable solution designed for intramuscular injection. The required oil carrier facilitates the necessary absorption of the lipophilic propionate ester into the bloodstream.

A key differentiating feature of the propionate ester is its shorter duration of action compared to other testosterone derivatives, necessitating more frequent administration to maintain stable levels.

Fundamental Action and General Benefit

Testovis functions by providing the necessary ligand to activate the body's androgen receptors within target cells, effectively substituting for deficient endogenous androgen. The administration of testosterone assists in restoring serum levels, thereby supporting overall vitality and function in men with diagnosed low levels.

This replacement action carries a significant anabolic effect, promoting protein synthesis stimulation in tissues such as skeletal muscle. By supplying this essential sex hormone, the medication helps stabilize and maintain crucial functions, including the support of male secondary sexual characteristics and the preservation of muscle mass and bone density, often compromised by androgen deficiency.

Regulatory References

  1. Testosterone Propionate Injection - USP-NF

What side effects are possible with Testovis (Testosterone)?

Possible Side Effects and Safety Information

The safety profile of testosterone propionate is formally classified by regulatory authorities based on the affected physiological systems and the frequency of occurrence. These effects are grouped into System-Organ Classes (SOCs) in official documentation, encompassing Blood and Lymphatic System Disorders, Reproductive System and Breast Disorders, Metabolism and Nutrition Disorders, and Skin and Subcutaneous Tissue Disorders.

Officially documented adverse reactions are often classified as Common (affecting 1 to 10 users in 100). These may include an increase in red blood cell count (polycythemia), fluid retention leading to edema, weight gain, acne, and benign prostatic changes. Changes in mood, nervousness, and gynecomastia are also documented among common effects.

The regulatory labels also identify Serious Adverse Reactions which, although rare, are clinically significant. These include the documented risk of thromboembolic events, such as deep vein thrombosis and pulmonary embolism, and the potential for hepatocellular neoplasms (liver tumours) associated with long-term, high-dose therapy. Existing conditions like sleep apnoea may also be exacerbated.

Specific Population-Specific Safety Considerations are detailed for certain patient groups. For older adults, enhanced monitoring for prostate pathology (carcinoma and BPH) is required. In prepubertal boys, the risk of premature closure of the growth plates must be monitored. The medicine is contraindicated in men with known or suspected prostate or male breast carcinoma, as stated in official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for testosterone products indicates that no reports of acute overdosage with androgens have been documented in some labels. Consequently, the primary focus of overdose guidance is on managing serious, life-threatening events associated with high-dose exposure or abuse.

Immediate medical attention is formally required if clinical manifestations of severe complications occur. You must seek medical attention immediately when experiencing symptoms such as chest pain, shortness of breath, trouble breathing, slurred speech, or sudden weakness in one side of the body, as these are documented signs of heart attack or stroke.


Documented Severe Outcomes

Prolonged use of high doses is associated with the risk of life-threatening outcomes, including hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis (liver toxicity). Additionally, venous thromboembolic events, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), are documented risks.

If a severe event is suspected, regulatory procedures mandate the discontinuation of treatment and the initiation of an appropriate workup and management. No specific antidote for acute androgen overdosage is officially documented. Patients with pre-existing cardiac, renal, or hepatic disease may be at increased risk for complications like edema and congestive heart failure.

Therapeutic Uses of Testovis (Testosterone)

What Testovis (Testosterone) Treats: Main Uses and Benefits

Testovis is primarily used as hormone replacement therapy in men diagnosed with male hypogonadism, a medical condition where the body produces abnormally low levels of Testosterone. This medication is indicated for use in men with low testosterone levels resulting from specific medical conditions. The treatment is relevant for easing symptoms that create noticeable physiological strain.

The medication is commonly used to help with a wide range of symptoms, which may include reduced libido, erectile dysfunction, loss of muscle mass and strength, and chronic fatigue. This therapy supports symptom management in clinical settings that involve acute or disruptive symptom patterns linked to systemic hormonal imbalance.

“The primary purpose of Testovis therapy is to address symptoms that may become more disruptive during flare-ups associated with the hormonal deficit.”

By providing this supportive relief, Testovis may assist with maintaining functional stability, contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Addressing Symptoms of Chronic Fatigue

Testovis may assist with managing symptoms related to low energy and difficulty concentrating, which are often linked to the underlying testosterone deficit. This is relevant when supportive symptom management is appropriate for symptoms that interfere with daily functioning.

Eligibility and Restrictions for Use

The official regulatory profile for injectable testosterone strictly defines which populations are eligible to use the medicine. Use is restricted to adult males with clinically and laboratory-confirmed testosterone deficiency (hypogonadism).

The medicine is contraindicated in specific groups as stated in the label:

  • Males with known or suspected carcinoma of the prostate or carcinoma of the breast.
  • Pregnant or breastfeeding women due to the risk of fetal and infant harm.
  • Patients with a documented hypersensitivity to the active substance or excipients.
Population Official Regulatory Status
Adult Males Permitted for diagnosed hypogonadism.
Pediatric Patients Safety and efficacy not established; use is not recommended due to risks to bone maturation.
Geriatric Patients Requires caution and monitoring for prostatic issues; limited clinical experience.

Use is further restricted and requires special consideration in patients with existing severe cardiac, hepatic, or renal disease because testosterone can promote fluid retention, potentially leading to or worsening congestive heart failure. Patients with polycythemia (high hematocrit) and uncontrolled hypertension also require careful monitoring as defined in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The use of Testovis (Testosterone) can alter the effects of certain other medicinal products, requiring dose adjustments and close clinical monitoring. The following key substance classes and specific medicines are officially documented to interact with testosterone:

Interacting Product Category Mechanism and Clinical Effect
Oral Anticoagulants (e.g., Warfarin) Testosterone may increase the effects of these medicines, leading to a higher risk of bleeding. The International Normalized Ratio (INR) and prothrombin time require frequent monitoring.
Antidiabetic Agents (e.g., Insulin) Testosterone may decrease blood glucose and subsequently reduce the requirements for insulin or other antidiabetic medicines. Patients with diabetes must have their blood sugar levels carefully monitored.
Corticosteroids (e.g., Prednisone) Concomitant use may result in increased fluid retention. This combination should be used with caution, particularly in patients who have pre-existing cardiac, renal, or hepatic disease, as fluid retention can exacerbate these conditions.

These interactions are primarily pharmacodynamic, affecting the clinical outcomes rather than the drug's metabolism. In cases of concurrent use, the dosage of the interacting medicine must be adjusted as necessary to maintain the desired therapeutic effect and minimize adverse risks.

Mechanism of Action

The core action of Testovis begins inside the cell, where the hormone Testosterone and its active metabolite, Dihydrotestosterone (DHT), act as agonists of the Androgen Receptor (AR), a type of nuclear transcription factor located in the cytoplasm. This binding initiates a genomic cascade where the active hormone-receptor complex translocates to the nucleus and controls the rate of gene transcription by binding to Androgen Response Elements (AREs).

This cellular mechanism leads to an anabolic physiological shift by promoting a positive nitrogen balance that increases protein synthesis in responsive cells. This process directly regulates the accrual of skeletal muscle mass and the maintenance of bone mineral density in target tissues. Additionally, the hormone exerts a negative feedback influence on the Hypothalamic-Pituitary-Gonadal (HPG) Axis, a central endocrine system, which suppresses the release of pituitary signals (Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH)), effectively reducing the body's own endogenous synthesis of testosterone.

Dosage and Administration Information

Administration Overview

Testovis is an injectable formulation of testosterone, typically presented in an oil-based solution. The administration process involves specific techniques and considerations to ensure the substance is delivered effectively and as intended by a healthcare professional.

Method of Delivery

This medication is designed for intramuscular (IM) injection. The solution is introduced deep into the muscle tissue, where it forms a depot that is gradually absorbed into the systemic circulation over time. Common sites for intramuscular injections include:

  • Gluteal muscle: The upper outer quadrant of the buttock.
  • Vastus lateralis: The lateral aspect of the thigh.
  • Deltoid: The upper arm muscle.

Selection of the injection site may depend on the volume of the solution and individual patient factors. Rotating injection sites is a standard practice to minimize local tissue irritation or the development of fibrous tissue.

Preparation and Handling

Proper handling of the ampoule or vial is a critical component of the administration process. Because the carrier is oil-based, the solution has a higher viscosity than aqueous medications. This characteristic often requires specific needle gauges to facilitate the withdrawal and injection of the fluid.

Before administration, the solution is visually inspected for particulate matter or discoloration. The integrity of the packaging is also verified to ensure the sterility of the contents. Once the medication is prepared, it is administered immediately to maintain aseptic conditions.

Procedural Considerations

The administration of an oil-based injectable requires a slow and steady technique. A rapid injection into the muscle can cause increased local pressure and discomfort. After the needle is withdrawn, light pressure may be applied to the site, though vigorous massaging is typically avoided as it might alter the absorption rate of the testosterone ester.

Waste materials, including used needles and empty glass containers, are managed according to protocols for the disposal of biohazardous sharps and medical waste to prevent accidental injury or environmental contamination.

Recent Clinical Evidence

Research evidence / Overview of studies for Testovis (Testosterone)

Evidence for Use in Diagnosed Male Hypogonadism

The core research examining testosterone replacement therapy, including formulations like Testovis, primarily involves Randomized Controlled Trials (RCTs) and Systematic Reviews. This research was studied for outcomes related to adult men diagnosed with low testosterone levels (hypogonadism). Researchers monitored key outcomes such as the restoration of serum hormone levels within the expected range, and applied in studies examining patient-reported experiences using standardized measures for sexual function and libido.

Findings describe patterns observed in the studies where participants experienced measured changes in their testosterone concentration. Research also highlights changes measured during the study period concerning patient-reported scores on sexual function indices. These studies help show what has been observed so far regarding changes in these key areas in the initial months of therapy.

Research on Associated Symptoms and Physical Outcomes

In addition to hormone levels, research explored outcomes related to systemic or functional imbalance, such as changes in body composition and physical function. Studies were applied in research contexts involving men with low testosterone. Research explored outcomes related to shifts in metrics like lean body mass and measures of muscle strength. These trials also monitored changes in bone mineral density (BMD), an outcome linked to physical structure and stability.

However, for highly subjective outcomes like non-specific chronic fatigue and general mood changes, findings were mixed across different studies. The research describes that the effect on these endpoints is often difficult to isolate, and results were sometimes inconsistent.

What is Still Uncertain About Testovis (Testosterone) Research

Several areas in the research exploring testosterone replacement therapy remain a source of uncertainty. Evidence quality varies across studies, particularly older trials, due to issues like modest sample sizes and different patient recruitment methods. Furthermore, the comparative evidence is lacking to definitively describe how the short-acting nature of a formulation like Testosterone Propionate compares to longer-acting forms of testosterone across a wide range of long-term outcomes. While many RCTs provided insight into short-term changes, their follow-up durations were limited, typically lasting only 6 to 12 months. This means there is limited information for long-term outcomes.

Key Studies & References A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE)

Frequently Asked Questions (FAQ)

Common questions about Testovis (Testosterone) (FAQ)


Q: How quickly does Testovis start working after the first application?

Testovis contains the testosterone propionate ester, which is an oil-based injectable designed for slow release from the injection site. Official information indicates that this formulation has a relatively short half-life compared to other testosterone products. Administration is managed by a healthcare provider, and the frequency is determined to help maintain hormone levels in the expected range.


Q: What should I expect in terms of how long the effects of Testovis last?

Official pharmacological information classifies Testovis (Testosterone Propionate) as having a shorter duration of action compared to other common testosterone derivatives. This is a characteristic of the propionate ester structure. Due to this shorter action, it is typically administered more frequently than longer-acting esters to help maintain consistent hormone levels.


Q: Do testosterone treatments like Testovis affect sleep or cause insomnia?

Regulatory safety information for testosterone products indicates that existing conditions such as sleep apnoea may be worsened by treatment. While not common, certain documentation has listed specific effects on sleep quality or insomnia as potential adverse reactions. Any change in sleep patterns should be discussed with the treating healthcare professional.


Q: What are the reported effects of Testovis on cholesterol levels?

Studies summarized in official product information suggest that testosterone treatments may affect serum lipids, which include cholesterol. Specifically, there is potential for testosterone to lower HDL ('good') cholesterol and elevate LDL ('bad') cholesterol levels. Patients with pre-existing high lipid levels may require close monitoring of these levels as defined in official prescribing information.


Q: Is there any known interaction between Testovis and alcohol consumption?

Regulatory documents do not typically specify a direct chemical interaction between the injectable solution and alcohol consumption. However, certain official resources note that alcohol use disorder (AUD) has been identified as one of the potential causes of low testosterone levels (hypogonadism) that Testovis is used to treat.


Q: Is Testovis used for treating conditions other than low testosterone levels in men?

While the primary and current approved use of Testovis is for hormone replacement therapy (HRT) in men with diagnosed low testosterone, testosterone propionate has had historical uses. These past uses include medical contexts outside of male hormone replacement, such as in the treatment of certain types of breast cancer.


Q: Why is Testovis not approved for men with 'age-related' low testosterone?

Regulatory agencies, including the FDA and the EMA, have stated that testosterone products are not approved to simply raise testosterone levels in healthy older men. Official regulatory warnings state that it is indicated when abnormally low testosterone is confirmed by both symptoms and required laboratory tests, not solely for 'age-related' changes.


Q: Are there studies that look at the long-term safety of using Testovis for many years?

Official overviews of clinical research have acknowledged that there is limited available information concerning the safety of testosterone therapy over very long periods. The follow-up durations for many clinical trials are typically short, meaning that information regarding outcomes over an extended period is limited in the current evidence base.


Q: Can Testovis affect my blood pressure readings?

Official regulatory warnings across the class of testosterone products note that treatment may cause an increase in blood pressure. Patients are monitored for this effect, and a healthcare professional manages any required adjustments in treatment.


Q: What is the difference between endogenous and exogenous testosterone in simple terms?

Endogenous testosterone refers to the hormone that the body naturally produces within organs like the testes. Exogenous testosterone, such as Testovis, is the synthetic or external hormone administered to the body to replace a deficient natural supply. The medication's role is to help supplement the body's deficient supply to achieve serum levels within a target range.


Q: What does the term 'secondary hypogonadism' mean in relation to Testovis use?

Secondary hypogonadism (or hypogonadotropic hypogonadism) is a specific type of low testosterone that occurs when there is a problem with the pituitary gland or hypothalamus in the brain. These glands fail to send the necessary signals to the testes. Testovis can be used to treat this condition, as well as primary hypogonadism (problems with the testes themselves).


Q: What if I have an allergic reaction to the ingredients in the Testovis formulation?

Official prescribing information states that the medication is contraindicated (should not be used) if a patient has a documented hypersensitivity to the active substance or any other inactive ingredients in the injection formulation. This warning is present because official prescribing information contraindicates use in patients with a documented hypersensitivity to the active substance or any of the inactive ingredients.


Q: Does Testovis cause changes in body fat distribution?

Official information indicates that testosterone deficiency itself is associated with an unhealthy increase in body fat, particularly visceral fat. Therapy with testosterone is studied for its potential to help support lean body mass and may be associated with changes in visceral fat levels.


Q: Does Testovis affect hair growth in areas other than the scalp?

Testosterone is classified as a primary male sex hormone that drives the development of male secondary sexual characteristics. These characteristics include the growth of face and body hair. Low levels of the hormone are associated with a lack of hair in these areas.


Q: What are the regulatory classifications for Testovis concerning safety during pregnancy for partners?

Regulatory bodies have given testosterone products a strict classification due to the risk of fetal harm. They are contraindicated in pregnant women because of the potential to cause abnormal development in a male fetus. For injectable forms, the risk of transfer is negligible, but overall pregnancy safety is a major regulatory consideration.


Q: Can Testovis interfere with diagnostic lab tests other than testosterone levels?

Official safety documents indicate that testosterone use may lead to a decrease in Thyroxine-binding Globulin (TBG). This substance is involved in thyroid hormone transport and can cause a change in certain blood test results, such as T4 concentrations. This change does not necessarily mean the patient has thyroid dysfunction.

How should Testovis (Testosterone) be stored and disposed of?

The storage and disposal of Testovis (Testosterone Propionate) must strictly adhere to the conditions documented in official regulatory labeling to maintain the product's integrity.

Storage and Handling Requirement Official Instruction
Temperature Condition Store below 25 C (or 77 F) [USP Controlled Room Temperature].
Prohibited Environment Do not refrigerate and do not freeze the injectable solution.
Environmental Protection Protect from light and keep in the original package until use.
Safety & Stability Keep the medicine out of the sight and reach of children; do not use after the expiry date.

Disposal instructions require that any unused or expired Testovis must not be thrown away with household waste or disposed of via wastewater (sinks or toilets). The product must be safely discarded according to local regulatory requirements for pharmaceutical waste to prevent environmental exposure. The oil-based solution requires specific temperature control to prevent crystallization.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Testovis (Testosterone) found in:

A-Z Index: